

Freedom of Information Request: Our Reference CTMUHB_134_23

You asked:

I have an FOI request which I hope you'll be able to help me with (questions are set out below)

Q1. In the past 3 months (latest 3 months available), how many patients have received the following treatments (for any disease):

- Berinert (Human C1-esterase inhibitor)
- Cinryze (Human C1-esterase inhibitor)
- Orladeyo (berotralstat)
- Takhzyro (Lanadelumab)
- Ruconest (Recombinant human C1-esterase inhibitor)
- Firazyr (Icatibant)
- Icatibant – any brand except Firazyr

Q2. In the past 3 months (latest 3 months available), how many patients have received the following immunoglobulin treatments (for any disease):

- Cutaquig
- Cuvitru
- Gammanorm
- Gammagard
- Hizentra
- Hyqvia
- Intratect
- Iqymune
- Kiovig
- Privigen
- Octagam
- Panzyga
- Subgam
- Any other normal immunoglobulin

Our response:

Please see provided below two tables populated with the data requested. The period the data covers refers to 1st December 22 to 28th February 23, the latest 3 months available.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q.1

Medicine	Number of Patients
Berinerit (Human C1-esterase inhibitor)	0
Cinryze (Human C1-esterase inhibitor)	0
Orladeyo (berotralstat)	0
Takhzyro (Lanadelumab)	0
Ruconest (Recombinant human C1-esterase inhibitor)	0
Firazyr (Icatibant)	0
Icatibant – any brand except Firazyr	0

Q.2

Medicine	Number of Patients
Cutaquig	0
Cuvitru	0
Gammanorm	0
Gammagard	0
Hizentra	0
Hyqvia	**
Intratect	**
Iqymune	**
Kiovig	0
Privigen	19

Octagam	0
Panzyga	0
Subgam	0
Any other normal immunoglobulin	
Flebogamma	**
Gamunex	13